Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328049460> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4328049460 endingPage "1028" @default.
- W4328049460 startingPage "1021" @default.
- W4328049460 abstract "What is this summary about? Few life-prolonging treatment options are available for patients with metastatic castration-resistant prostate cancer (mCRPC). This article provides an overview of the current systemic treatments available for mCRPC and reviews studies that investigate the optimal timing for the use of radium-223. The aim is to illustrate possible systemic treatment sequences to maximize benefit from radium-223 therapy. What is metastatic castration-resistant prostate cancer & how is it treated? Prostate cancer is called mCRPC when it spreads to organs outside of the prostate (such as the lymph nodes, bones, liver, or lungs) and no longer responds to hormonal therapy. There are several treatment options available for mCRPC, such as abiraterone, enzalutamide, radium-223, docetaxel, cabazitaxel, olaparib, rucaparib, sipuleucel-T, and 177Lu-PSMA. It is important to understand the risks and benefits associated with each treatment and whether current use may have an impact on future treatment options, including eligibility in certain clinical trials. Maintaining bone health is also an important part of prostate cancer care. What is radium-223? Radium-223 is a radioactive molecule that releases strong radiation within a very small range around itself. It mainly travels to the bone where the prostate cancer has spread and kills the cancer cells in that area. Results from a clinical study named ALSYMPCA showed that men who received radium-223 lived longer in addition to having less bone pain. The most common side effects of radium-223 are nausea, vomiting, and diarrhea. Radium-223 minimally suppresses the bone marrow, which means that it slightly reduces the levels of red and white blood cells." @default.
- W4328049460 created "2023-03-22" @default.
- W4328049460 creator A5047078570 @default.
- W4328049460 creator A5048994559 @default.
- W4328049460 creator A5085520095 @default.
- W4328049460 date "2023-05-01" @default.
- W4328049460 modified "2023-10-01" @default.
- W4328049460 title "Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary" @default.
- W4328049460 doi "https://doi.org/10.2217/fon-2022-1296" @default.
- W4328049460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36942803" @default.
- W4328049460 hasPublicationYear "2023" @default.
- W4328049460 type Work @default.
- W4328049460 citedByCount "0" @default.
- W4328049460 crossrefType "journal-article" @default.
- W4328049460 hasAuthorship W4328049460A5047078570 @default.
- W4328049460 hasAuthorship W4328049460A5048994559 @default.
- W4328049460 hasAuthorship W4328049460A5085520095 @default.
- W4328049460 hasBestOaLocation W43280494601 @default.
- W4328049460 hasConcept C121608353 @default.
- W4328049460 hasConcept C126322002 @default.
- W4328049460 hasConcept C143998085 @default.
- W4328049460 hasConcept C2776551883 @default.
- W4328049460 hasConcept C2777783956 @default.
- W4328049460 hasConcept C2777899217 @default.
- W4328049460 hasConcept C2778971682 @default.
- W4328049460 hasConcept C2780192828 @default.
- W4328049460 hasConcept C2780737065 @default.
- W4328049460 hasConcept C2781190966 @default.
- W4328049460 hasConcept C509974204 @default.
- W4328049460 hasConcept C61367390 @default.
- W4328049460 hasConcept C71924100 @default.
- W4328049460 hasConceptScore W4328049460C121608353 @default.
- W4328049460 hasConceptScore W4328049460C126322002 @default.
- W4328049460 hasConceptScore W4328049460C143998085 @default.
- W4328049460 hasConceptScore W4328049460C2776551883 @default.
- W4328049460 hasConceptScore W4328049460C2777783956 @default.
- W4328049460 hasConceptScore W4328049460C2777899217 @default.
- W4328049460 hasConceptScore W4328049460C2778971682 @default.
- W4328049460 hasConceptScore W4328049460C2780192828 @default.
- W4328049460 hasConceptScore W4328049460C2780737065 @default.
- W4328049460 hasConceptScore W4328049460C2781190966 @default.
- W4328049460 hasConceptScore W4328049460C509974204 @default.
- W4328049460 hasConceptScore W4328049460C61367390 @default.
- W4328049460 hasConceptScore W4328049460C71924100 @default.
- W4328049460 hasIssue "15" @default.
- W4328049460 hasLocation W43280494601 @default.
- W4328049460 hasLocation W43280494602 @default.
- W4328049460 hasOpenAccess W4328049460 @default.
- W4328049460 hasPrimaryLocation W43280494601 @default.
- W4328049460 hasRelatedWork W122177069 @default.
- W4328049460 hasRelatedWork W2015876133 @default.
- W4328049460 hasRelatedWork W2021751111 @default.
- W4328049460 hasRelatedWork W2072037375 @default.
- W4328049460 hasRelatedWork W2135620818 @default.
- W4328049460 hasRelatedWork W2400161037 @default.
- W4328049460 hasRelatedWork W2568045406 @default.
- W4328049460 hasRelatedWork W2768013934 @default.
- W4328049460 hasRelatedWork W3132581442 @default.
- W4328049460 hasRelatedWork W3145698220 @default.
- W4328049460 hasVolume "19" @default.
- W4328049460 isParatext "false" @default.
- W4328049460 isRetracted "false" @default.
- W4328049460 workType "article" @default.